Erich Mohr - 08 Dec 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Reporting relationship: Director
Issuer ticker: ERNA
Reported as of: 08 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Dec 2021, 20:00:47 UTC
Prior SEC filing: 26 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Mark L. Johnson, Attorney-in-Fact for Erich Mohr

Key filing fact

Erich Mohr filed Form 4 for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 10 Dec 2021.

Key facts

This page summarizes Erich Mohr's Form 4 filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Dec 2021, 20:00.

Change

Previous filing in this sequence was filed on 26 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +67,000
Change %
Price: $0.000000
Shares after: 67,000
Date: 08 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,000
Exercise price: $5.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.